Starting with Micro Perspectives and Leading with Innovation

Yantai Lannacheng Biotechnology Co., Ltd. (hereinafter referred to as LNC), headquartered in the beautiful beach city of Yantai, was jointly founded in 2021 by Yantai Dongcheng Pharmaceutical Group Co., Ltd. (hereinafter referred to as DC Pharma), one of China’s leading nuclear medicine enterprises, and Professor Xiaoyuan (Shawn) Chen, a world expert in molecular imaging and nanomedicine field. LNC is committed to developing novel radiotheranostics, which is a critical part of DC Pharma’s nuclear medicine ecosystem.

LNC owns a large-scale comprehensive laboratory located in “Yantai MediPark”, built in 2023 with an investment of over 100 million RMB, with about 6,500 m² lab space, capable of drug synthesis, radiolabeling, preclinical study, molecular imaging, and therapy experiments, marking the establishment of LNC’s “molecular screening and translational medicine core technology platform”, which will greatly advance the R&D process of LNC’s innovative radiopharmaceuticals.